Publications
2023 International on Alzheimer's and Parkinson's Disease and Related Neurological Disorders (AD / PD) Conference
March 28 – April 2, 2023 | Gothenburg, Sweden
Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s Disease: A Phase 2, Double-Blind, Placebo-Controlled Study
Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s Disease
2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 29 – December 2, 2022 | San Francisco, California
Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
